Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Roivant Sciences Ltd. (ROIV) had Consolidated Net Income/Loss of $355.74M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$2.52M |
|
$302.99M |
|
$0.32M |
|
$2.20M |
|
$-412.72M |
|
$415.24M |
|
$38.86M |
|
$454.10M |
|
$480.02M |
|
$355.74M |
|
$355.74M |
|
|
Consolidated Net Income/Loss |
$355.74M |
$387.28M |
|
$415.24M |
|
-- |
|
702.13M |
|
812.29M |
|
$0.43 |
|
$0.28 |
|
| Balance Sheet Financials | |
$5.06B |
|
-- |
|
-- |
|
$5.71B |
|
-- |
|
-- |
|
-- |
|
$416.27M |
|
-- |
|
$5.29B |
|
$5.29B |
|
-- |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|